Taste Physiology in Healthy, Normal-weight Volunteers

Exploratory Behavior Clinical Trial

Official title:

Taste Physiology in Healthy, Normal-weight Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02255812
• Other study ID #: EKBB 289/12/2
• Status: Completed
• Phase: N/A
• First received: August 6, 2014
• Last updated: September 30, 2014
• Start date: March 2013
• Est. completion date: October 2013

Study information

• Verified date: September 2014
• Source: University Hospital, Basel, Switzerland
• Contact: n/a
• Is FDA regulated: No
• Health authority: Switzerland: Ethikkommission
• Study type: Interventional

Clinical Trial Summary

Taste physiology describes five main taste qualities in humans: sweet, sour, salty, umami and bitter. The receptors found on the tongue are also found in the entire gut. The correlation of stimulation of these gut receptors and brain activity has not yet been examined. The objectives are to investigate the effect of different taste substances on i) regional brain activity and ii) satiation peptide release.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: October 2013
• Est. primary completion date: October 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• right-handed healthy males

• Body-mass index of < 25

• Age 18-45 years

• no drugs

• non-smoking

Exclusion Criteria:

• Smoking

• Substance abuse

• Regular intake of medications (except for oral contraceptives)

• Medical or psychiatric illness, especially: diabetes, pace-maker, claustrophobia

• History of gastrointestinal disorders

• Food allergies, glutamate intolerance

• Body piercings that cannot be removed

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Exploratory Behavior

Intervention

Dietary Supplement:
• Single intragastric instillation of 200 mL tap water via nasogastric tube

• Single intragastric instillation of 2 g citric acid in 200 mL tap water via nasogastric tube

• Single intragastric instillation of 2 g salt in 200 mL tap water via nasogastric tube

• Single intragastric instillation of 0.017 g quinine in 200 mL tap water via nasogastric tube

• Single intragastric instillation of 1 g monosodium glutamate in 200 mL tap water via nasogastric tube

• Single intragastric instillation of 25 g glucose in 200 mL tap water via nasogastric tube

Locations

Country	Name	City	State
Switzerland	University Hospital	Basel

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	regional brain activity assessed by functional Magnetic Resonance Imaging (fMRI)	Changes in resting state functional connectivity	changes from baseline to one hour after treatment	No
Secondary	gastrointestinal satiation peptide secretion	Unit of Measure: glucagon like peptide-1 (GLP-1) in pg/mL, peptide tyrosine tyrosine (PYY) in pg/mL and gastric inhibitory polypeptide (GIP) in pg/mL	changes from baseline to one hour after treatment	No
Secondary	glucose and insulin secretion	Unit of Measure: glucose in mmol/L, insulin in µU/mL	changes from baseline to one hour after treatment	No